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ABSTRACT: Innovation in R&D is a key target for the pharmaceutical sector to address some of the challenges it currently 
faces. This review discusses these challenges in the context of pharmaceutically relevant surfaces and interfaces. The surface 
properties of materials determine many pharmaceutically important interactions and can be drastically different from the 
material’s bulk properties. We first introduce current challenges in the surface and interface analysis of pharmaceutical 
materials in the context of design, administration and fabrication. We then review recent scientific and technological advances 
aimed to address these issues and shortly discuss a small number of examples to illustrate the capabilities of these techniques. 
 
 
 
1. INTRODUCTION 
 
 
The last decade has presented the pharmaceutical industry with a number of challenges that are expected to affect the long 
term business models of pharmaceutical companies.
1, 2
 Concerns relating to aspects of drug safety and efficacy impact the 
public image of the pharmaceutical sector. Together with the expiration of several key patents in 2010-2014, these 
developments affect the valuation and profitability of pharmaceutical products.
1
 
 
Innovation in R&D and a clear demonstration of the value of pharmaceutical products have been identified as key aspects to 
tackle these issues.
1, 3-5
 However, the development of pharmaceutical products is highly challenging and traditionally associated 
with long and costly development phases. Reforming these processes to minimise risk of failure and reduce development cost 
has therefore been proposed as a core requirement to reform pharmaceutical development.
1, 4-6
 
 
Key aspects for innovation in drug development are to improve the predictability of the properties, performance and production 
of drugs and to establish mechanisms that enable early go/no-go decisions.
1, 3
 To realise this, it is paramount that we overcome 
current limitations in our understanding of how drugs interact with the body and their co-formulated excipients both on an 
organism and a molecular level.
3
 Besides the development of new biomarkers, analytical tools able to assess drug performance 
in pre-clinical and clinical tests are required. 
1, 3
 Many of these analytical challenges revolve around interfacial biological 
processes; consequently, surface and interface analysis has the potential to contribute significantly to these challenges and 
support the development of new approaches for pharmaceutical analysis. 
 
It is broadly recognised that such an endeavour in innovation is no longer practical to be carried out by individual 
organisations;3, 7 industry, academia and public and governmental organisations will have to collaborate to tackle the 
challenges that the pharmaceutical sector currently faces. The development of reliable analytical tools requires both 
cutting edge scientific and technological innovation as well as the establishment of measurement standards, traceable 
procedures and quality control. Joint centres between academia and national measurement institutes such as the Interface and 
Surface Analysis Centre (ISAC), a University of Nottingham centre of excellence in partnership with the National Physical 
Laboratory, take advantage of the complementary strengths from both academia and industry. In such collaborative efforts, 
2 
 
academia has the potential to fill gaps in science and provide access and expertise to innovative procedures and 
equipment that is otherwise unavailable to pharmaceutical companies.3 
 
In the following review, we will identify the challenges and opportunities presented by surface and interfacial analysis in 
pharmaceutical problems. We will then provide a brief account of recent technological advances for a selected number 
of techniques, accompanied by a number of examples to illustrate their application potential for pharmaceutical 
problems. 
 
 
 
 
2. CHALLENGES IN PHARMACEUTICAL CHARACTERISATION 
 
 
Surface and interface analysis has become an integral part of pharmaceutical research and technology development. 
Advances in analytical capabilities have contributed significantly to understanding of the performance of pharmaceutical 
products; yet, significant challenges remain. The nature of these challenges is diverse and ranges from science and technology 
to management and infrastructural aspects. Some of them are highlighted in Figure 1 and will be discussed below in the 
context of design, administration and manufacturing of pharmaceutical products. 
 
 
 
Figure 1. Key challenges in surface and interface analysis for pharmaceutical applications. 
 
 
 
2.1. Characterising pharmaceutical formulations 
 
Physicochemical  properties of pharmaceutical formulations, next to other aspects such as potency, scalability, cost etc., are 
among the main factors that drive pharmaceutical performance and efficacy.
3
 For example drug availability, stability and the 
rate of dissolution can vary greatly with properties such as morphology, roughness and drug distribution in a matrix.
8, 9
 Equally, 
the chemical properties of a surface affect the interaction of materials at an interface within a system or indeed between that 
system and its environment. Identifying and characterising these properties is therefore essential to understand why 
formulations are successful or fail. 
 
It is the understanding of these surfaces and interfacial properties and interactions that are particularly important. Bulk chemical 
and physical analytical methods such as NMR, infrared spectroscopy, traditional mass spectrometry, x-ray diffraction, dynamic 
light scattering etc. have been the mainstay of material characterisation catalogues.
10
 While providing necessary and important 
information, these techniques do not offer insight into interfacial and surface phenomena. For example, active pharmaceutical 
ingredient (API) distribution and morphology can be markedly different on the surface of a tablet as compared to the bulk 
material.
11
 Standard bulk characterisation techniques are unable to identify these subtle differences whereas surface sensitive 
analysis techniques are able to distinguish between the top molecular layer and the bulk of the material. 
 
 
 
2.2. Administration and interaction 
 
Characterising spatial and temporal changes of the API composition (stability) and distribution in a formulation during uptake 
and release is essential to understand drug performance. As the interactions of a tablet or drug delivery particle with its 
biological surrounding takes place at the solid-liquid interface, characterising surface and interfacial properties of the 
formulation become extremely important.
11, 12
  However, analysing these materials and their surfaces under physiologically 
relevant conditions presents a significant challenge. Routine dissolution tests only provide limited information about the 
distribution of APIs within a tablet.
8
 Surface analysis techniques such as X-ray photoelectron spectroscopy (XPS) and mass 
spectrometry have been used but for these ex-situ methods the effect of sample preparation for analysis in low pressure 
environments is a critical issue.
8
 The continued development of surface analysis techniques operating under near ambient 
conditions 
13, 14
 has the potential to address this issue. 
 
Knowledge of where in the body and in the cell the APIs accumulate is an important aspect related to drug efficacy and 
toxicity.
3
 Mass spectrometry techniques are able to identify and image (both in 2D and 3D) APIs in biological tissue in a label-
free manner.
15
 While subcellular resolution is accessible, major challenges remain to increase the spatial and mass resolution 
3 
 
as well as the sensitivity of these techniques 
16-18
 to enable insight into molecular level interactions of APIs with cells.
15
 
Moreover, issues with the preparation of complex biological samples and the effect of matrices on the mass spectra need to be 
addressed.
8, 18
 
 
 
 
2.3. Manufacturing, packaging and quality control 
 
Drug development not only requires the design or discovery of APIs with appropriate targets and uptake characteristics, the API 
also has to be stable and able to be produced in a scalable manufacturing process in an appropriate dosage form.
3
 The surface 
of solid dosage forms plays a major role during manufacturing, packaging and quality control of pharmaceutical products.
19, 20
 
These interactions must be understood and well controlled to prevent undesired interactions, inter-batch variability or 
contaminations that affect the performance of the formulation.
8, 19
 
 
While these aspects of surface analytics are unlikely to present significant scientific challenges in terms of analysis, selection 
and availability of the correct techniques may represent a barrier. Translation of knowledge and cooperation between industry 
and academia is essential to address these aspects and support the development of the pharmaceutical industry towards more 
efficient R&D models.
21
 
 
 
 
3. RECENT ADVANCES IN SURFACE AND INTERFACE ANALYSIS 
 
A key element in meeting the challenges described above is the ability and capacity to adapt to advances in technical and 
operational methodologies. The routine bulk characterisation techniques discussed above are often favoured due to their 
established capabilities and operational familiarity which inherently conforms to a heavily regulated framework. This comes with 
the risk that novel methods and developments can be negatively selected against, which presents an obstacle to efficient 
development. Subsequently, we will discuss a series of advances in surface and interface analysis pertinent to pharmaceutical 
research that have potential to function as powerful research tools and help address the challenges outlined (Figure 2). We will 
particularly highlight the possibility to study the distribution of non-labelled APIs in 3D and recent developments towards 
measuring surfaces and interfaces of pharmaceutically relevant samples under ambient conditions. 
 
 
 
Figure 2. Some state of the art surface and interface analysis tools and technologies. Images reproduced with permission from 
ISAC and NPL (in parts © Crown copyright, Courtesy of NPL). 
 
 
3.1. Cluster source depth profiling 
 
Polyatomic ion sources used with surface sensitive analytical techniques such as XPS and Time-of-Flight Secondary Ion Mass 
Spectrometry (ToF- SIMS) have been fundamental to advances in organic sample analysis. The ability to profile the chemistry 
of organic materials was enabled by the development of cluster ion sources that provide increased sputter yields in conjunction 
with reduced subsurface damage.
22
 With depth sensitivities as low as 5-10 nm, these ion sources allow multilayer or composite 
materials to be chemically characterised in 3D. However some complex pharmaceutically relevant materials such as cross-
linked polymers and hydrogels have continued to prove difficult to analyse with traditional cluster sources such as C60
n+
. 
Significant damage accumulation persists, causing a rapid loss in secondary ion signal and sputter yields.
23
 
 
The recent development of Argon gas cluster beam technologies (Arn
+
) has addressed these issues. Arn
+
 sources showcase a 
significant reduction in chemical damage, with the capacity to achieve constant depth resolution and sputtering yields rarely 
seen using C60
n+ 
(see for example Fig 3 D).
24
 Therefore, the growing number of XPS and ToF-SIMS facilities with an Argon 
cluster source havethe capacity to characterise the spatial and lateral surface specific chemistries of a broader range of organic 
substrates without labelling, to an almost unrivalled resolution. Furthermore, the distinct differences in sputter yield that Arn
+
 
sources provide on organic and inorganic materials can be used to directly localise and manipulate organic/inorganic 
interfaces.
25
 Translation of this technology to investigate medical devices such as drug loaded polymeric stents or impregnated 
surgical implants/scaffolds has the potential to offer an avenue to better characterise the fundamental physicochemical 
properties of complex and novel pharmaceutical vehicles and devices (see for example Figure 3 B). Such investigations may 
provide significant insight into the formulation and structure-function relationship of APIs that drives their performance. 
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3.2. Ionic liquid X-Ray photoelectron spectroscopy 
 
XPS has increasingly been utilised to analyse the surface chemistry of novel drug delivery formulations, in particular with 
respect to the process of micro particle fabrication for drug delivery
9, 26-28
 XPS’ ability to characterise both the elemental and 
chemical state of the surface makes it almost uniquely capable of identifying and quantifying the functional chemistry.
29
 
However the technique requires ultra-high vacuum (UHV) conditions to avoid electron scattering by a gas phase and ensure 
sample cleanliness. This has precluded the analysis of materials unstable in a vacuum, including liquid formulations and many 
biopharmaceutical products. However recent advances in the area have opened up the capacity to work with a broader range 
of materials and expand the utility of XPS into additional applications. 
 
Ionic liquids are salts with melting points below 100˚C, (some are liquid at room temperature) that possess ‘extremely low 
volatility, unusual solvation and miscibility characteristics, a large electrochemical window, high thermal stability, 
nonflammability and electroconductivity’.
30
 They have potential application in the pharmaceutical industry either as APIs 
themselves, or as solvents or co-solvents for the delivery of drugs with poor water solubility.
31
 This interest has been driven by 
the capacity to adjust the properties of an ionic liquid formulation by altering the ionisable functional groups to overcome poor 
solubility, bioavailability issues, stability and polymorphism and foster new delivery options such as slow release systems.
32
 
Over last decade, it was established that the volatility of ionic liquids is low enough to render them stable in UHV conditions and 
will not contaminate sensitive operational systems. As such the nanometre resolution and ppm / ppt sensitivities of UHV 
surface analytics can now be applied to ionic liquid systems. The introduction of unique XPS facilities dedicated to these 
liquids, such as the LiPPS (Liquid Phase Photoelectron Spectroscopy) instrument at the University of Nottingham, presents an 
opportunity to develop the surface characterisation of a potentially revolutionary formulation component, or utilise them as a 
medium for more abstract sample presentations. 
 
 
3.3. Ambient mass spectrometry techniques 
 
A significant number of technical developments in the mass spectrometry field (and indeed with other chemical analysis tools 
such as confocal Raman) have been complemented with expanding operational experience that has significantly increased the 
capacity for ‘in-situ’ analysis of a broadening range of samples. Desorption electrospray Ionization mass spectrometry  
(DESI), liquid extraction surface analysis (LESA), plasma assisted desorption ionization mass spectrometry (PADI) are all 
ambient mass spectrometry techniques that have been developed to not simply spectrally analyse complex samples with high 
mass sensitivities, but also chemically map  them to determine distributions of biomolecules.
33
 In conjunction with other related 
ionization techniques such as matrix assisted laser desorption mass spectrometry (MALDI), biological samples such as brain 
tissue have been characterised without extensive pre-treatment or labelling under ambient or in-situ conditions (see for 
example Figure 3 A).
33
 This lends itself towards trains of analysis such as the permeation of APIs (particularly proteins) through 
skin, and the localisation of chemical components in a given physiological system.
34-36
 The spatial resolution of these 
techniques is constantly improving (currently tens to hundreds of microns), and has contributed to their developing catalogue of 
applications.
37
  
 
 
3.4. Coherent Raman scattering 
 
Traditional Raman spectroscopy relies on the spontaneous inelastic scattering of light to generate spectra unique to a 
material’s molecular composition and state. However, such spontaneous scattering is typically very weak (the scattered 
intensity is about 10
-6
 less than that of the incident radiation
38
) and therefore imaging based on this process tends to be very 
slow (although improving rapidly). Furthermore spectra may sometimes struggle with broad features due to a sensitivity to 
conformational differences in structure, differences in environment and rapid dephasing processes, giving rise to feature 
overlap and an occluded spectra.
39
 Coherent Raman scattering techniques offer a solution to this, by using non-linear excitation 
to enhance the scattering signal. By using simultaneous excitation with two laser beams at different frequencies, when the 
difference in the two frequencies match that of a given molecular vibration, the interaction of the beams and the sample give 
rise to a coherent vibrational motion, greatly enhancing the signal.
40
  
 
Coherent anti-stokes Raman scattering (CARS) and stimulated Raman scattering (SRS) are the two principal variations of this 
technique and have been available for some time, but it has been with recent technical updates in non-linear optics and laser 
technologies that the potential applications have grown. These techniques are now capable of offering video speed imaging, 
dynamic assessment of vibrational coherences as well as higher spectral resolutions. The ability of Raman techniques to 
operate under ambient or environmentally controlled conditions, in-situ and to detect subtle physicochemical changes 
(polymorphisms, crystallinity etc.) without labelling makes such adaptations very attractive for real time tissue or cellular 
imaging, API localisation, and/or dynamic API response monitoring. Recent examples of pharmaceutically pertinent 
applications include non-invasive 3D permeation assessment of API delivery through skin,
41
 the real time dissolution analysis of 
an oral dosage form
42
 and the characterisation of binder distribution in API-sugar-polymer granules (see Figure 3 C).
43
 
 
 
3.5. Tip enhanced Raman scattering 
 
Another emerging Raman technique is tip enhanced Raman scattering (TERS). TERS developed over the last decade as a 
high resolution variant of surface enhanced Raman scattering (SERS).
44
 In SERS, the ability of light to excite localised surface 
plasmon resonance (LSPR) and the associated enhancement of the electromagnetic field on the surface of nanostructured 
materials are used to amplify the inherently weak Raman scattering cross section.
45, 46
 In TERS, a similar effect is achieved on 
a single nanostructure that forms the tip of a scanning probe microscope.
44
 Coupling light into the metal tip essentially 
generates a near field light source that can be scanned across a sample surface. The deterioration of the near field over 
distance makes the technique highly surface sensitive while the lateral size of the evanescent field offers spatially resolved 
measurements that typically reach a resolution of 10 nm
44
 although resolutions down to 4 nm have been reported.
47
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While the potential of high resolution spectral imaging with TERS is evident, a number of challenges remain to be addressed 
before the technique will find broader application. One of the main remaining issues currently is the reproducible manufacture 
of metal tips in order to obtain a stable field enhancement.
44
 For other issues such as the background signal resulting from the 
far field illumination and the generation of artefacts due to thermal drifts, fluctuations of the signal intensity etc., solutions have 
been proposed.
48-51
 The application of TERS in liquid environments has been reported to be feasible,
52, 53
 but the liquid 
surrounding introduces other challenges such as tip contamination and stability that have to be addressed.
44
  While TERS still 
requires significant development before it will become a routine surface analysis technique, the attractiveness of obtaining 
spectra of sample surfaces with nanometre resolution on biological samples such as lipids, cells and biominerals has already 
generated considerable interest
54
. Thisis likely to see TERS become a major tool in the analysis of pharmaceutical samples ex- 
and in-vivo 
 
 
3.6. 3D NanoSIMS 
 
Announced at the back end of 2013, the National Physical Laboratory (NPL) confirmed the development of a new 3D 
nanoSIMS system. The project is a pioneering collaboration between the National Centre of Excellence in Mass Spectrometry 
Imaging (NICE-MSI) at NPL, GlaxoSmithKline (GSK), ION-TOF, Thermo Scientific and academics from the University of Illinois 
and the University of Nottingham. The project builds upon the achievements of the pre-existing CAMECA nanoSIMS 
instrument. These current machines use a specific alignment of primary and secondary ion beams that allow the primary 
focussing lens to be closer to the sample, thereby reducing focussing aberrations.
55
 This has allowed spatial resolutions of 
down to 50 nm, but is limited to elemental information in 2D, with appropriate labelling and mechanical sectioning.
55
 The 3D 
nanoSIMS instrument is being designed to match the spatial resolution of the current nanoSIMS while providing 3D, label-free, 
molecular imaging. These adaptations will open the door to even more versatile, unadulterated measurements of intracellular 
API concentrations and localisation at a cellular (and perhaps cell site) level. While still under manufacture, this potentially 
revolutionary instrumentation development is a prime example of the unique and positive outcomes of collaborations between 
academia and industry in refining approaches to pharmaceutical development. 
 
 
 
Figure 3. Examples of pharmaceutical applications of surface and interface analysis. A. Ambient ionization mass spectrometry 
(DESI) provides label free chemical maps of rat brain slices. Reproduced by permission of The Royal Society of Chemistry from 
reference 
56
 B. Application of argon cluster sources in ToF-SIMS to chemically image the distribution of lysozyme (red) in 
polymer microspheres (PLGA = green, PVA = blue). (Reproduced without further adaptation from reference 
57
 under the 
creative commons license.) C. Stimulated raman scattering microscopy of amlodipine tablets from two different suppliers 
showing different API distributions (green: cellulose; blue: calcium phosphate; red: amlodipine besylate; magenta: magnesium 
stearate; yellow: sodium starch glycolate for Pfizer and corn starch and lactose monohydrate for Apotex. Reproduced by 
permission of The Royal Society of Chemistry from reference 
58
. D. 3D ToF-SIMS image of a model layer system of polystyrene 
(PS) and polyvinylpyrrolidone (PVP) on glass obtained with an argon cluster source. Reproduced with permission from J. 
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Bailey, R. Havelund, J. S. Sharp, A. G. Shard, I. S. Gilmore, M. R. Alexander, and D. J. Scurr, “Argon cluster ion beam depth 
profiling of polymer multi-layer films”. Image courtesy of Dr David Scurr, University of Nottingham. 
 
4. CASE STUDIES 
 
4.1. Coherent Raman scattering characterisation of drug disposition 
 
The advancement of coherent Raman scattering technologies and the growing catalogue of published SRS and CARS 
research applications could provide the basis for updated and streamlined pharmaceutical analysis protocols. As discussed in 
section 3.4, a principal advantage of these newer techniques is the potential for label free, in-situ chemical imaging at video 
speed with high resolution. Some recent examples of published work showcase the particular strengths of these techniques in 
their application to assessments of drug disposition. Belsey et al. demonstrated the capacity of coherent Raman scattering to 
characterise topical pharmaceutical delivery through skin tissue.
41
 In this work both SRS and CARS were used to visualise and 
measure ketoprofen and ibuprofen as well as nanoparticle delivery through porcine skin. Characterisation was performed in 3D, 
showcasing the formulation at the surface, skin penetration of the API, the drug delivery pathways and final API localisation.  
 
SRS allowed semi-quantitative concentration gradients to be measured through skin layers. This was achieved with 
simultaneous 3D visual localisation of the transport pathways of the APIs and physical characterisation of changes to the 
formulation e.g. crystallisation of API at the surface. Nanoparticulate delivery uptake into thermally ablated channels was also 
characterised in 3D using CARS.
41
 These analyses were performed without the need to employ traditional sequential skin 
stripping preparation that is invasive and labour intensive. Furthermore, the Raman techniques enabled small nanoparticles 
(~40nm diameter) to be resolved individually beyond the resolution capability of fluorescent microscopy.  
 
Other research showcases equally impressive and diverse results; for example, using SRS Wei et al. characterise (among a 
range of processes including DNA synthesis etc.) the spatial distribution of the antifungal drug terbinafine hydrochloride and its 
delivery pathway into ear tissue.
59
 By using Raman sensitive, alkyne tags, bulky and pharmacokinetically damaging 
fluorophores were avoided and live imaging in-vivo was possible. 
 
Other applications of these techniques have exploited the increased speed and resolution possible with CARS imaging to 
investigate pharmaceutical dosage forms. Fussell et al. imaged the dissolution of theophylline anhydrate from a series of 
formulations and related real-time changes of surface content and morphology to a concurrent UV dissolution profile.
60
 
Importantly, growth of theophylline monohydrate crystals could be visualised and associated with a decrease in dissolution rate. 
Fonteyne et al. used CARS to visualise and prove homogeneous binder distribution within granules produced by twin screw wet 
granulation.
43
 Hartshorn et al. used the improved spatiochemical resolution of CARS to confirm a previously unidentified API 
phase in an Indomethacin dosage form while operating with 10x faster speeds than conventional Raman spectroscopy.
61
 Such 
examples highlight how recent advances in the coherent Raman scattering field offer the capability to perform real time 
chemical imaging for a broadening range of pharmaceutical analyses. 
 
 
 
4.2. Imaging of biomolecules in tissue with ToF-SIMS 
 
 
In section 2 we highlighted the importance of identifying specific biomolecules or drugs within a biological sample – either tissue 
sections or individual cells – in a spatially and temporally resolved manner. ToF-SIMS is one technique where technical 
developments have expanded the potential for unlabelled, high resolution 3D chemical mapping. Localisation of molecules in 
biological samples is becoming increasingly accessible due to the ongoing developments in cluster sources for SIMS 
techniques discussed in section 3.1..
62
 The introduction of the C60
+
 cluster source opened up the ability to depth profile cells 
using mass spectrometry. While initially large cells (oocytes) were used,
63
 improved operational and data analysis procedures 
have increased the spatial resolution and quality of 3D MS cell imaging,
63-65
 providing for example 3D images of fibroblasts.
65
 
One particular example demonstrates that ToF-SIMS of HeLa cells using C60
+
 cluster ion beams to sputter the biological 
sample and a Bi3
+
 liquid metal ion gun to analyse it in a layer by layer fashion is able to provide 3D chemical maps of the cells 
when the sample is z-corrected on the basis of a combined atomic force microscope image.
64
 The distribution of a non-native 
compound, bromodeoxyuridine, a nuclear marker, was thus visualised and shown to be localised at the nucleus of the cell, 
demonstrating the ability of the technique to provide label free chemical maps of drugs within biological samples.  
 
SIMS imaging of tissue samples in 2D has already advanced to pre-clinical applications. For example, the skin penetration of 
topically applied drugs (roflumilast, tofacitinib, ruxolitinib, chlorhexidine) was evaluated in cross sections of mouse ears and 
porcine skin
66, 67
 and the distribution of various biomolecules (non-alcoholic fatty acids, cholesterol, vitamin E) was visualised in 
liver biopsies obtained from human patients.
68
 Advancing the application of 3D SIMS imaging to tissue samples, the recently 
developed argon cluster source was employed to generate a 3D chemical map of a 14 m thick rat brain tissue.
69
 Dual beam 
depth profiling, using Ar1500
+
 for sputtering and Bi3
+
 for analysis, was used to generate a 3D image of the rat brain slice in which 
the distribution of phosphocholine (PC) and cholesterol as well as the presence of the silicon wafer substrate were visualised in 
a label free manner. It was shown that cholesterol was mainly localised near or at the sample surface but that it also generated 
a strong matrix effect, affecting the ionisation of other lipids. Notably, it was shown that argon cluster sources are capable of 
producing 3D chemical images of biological samples with a markedly increased sensitivity.  
 
The studies highlighted here demonstrate the usefulness of the techniques to clinically relevant research and show the wealth 
of information made accessible by the ongoing advances in mass spectrometry imaging, most notably the label free detection 
of drugs and other biomolecules with high sensitivity and subcellular spatial resolution in three dimensions. These capabilities 
are expected to play an important role in assessing the performance, uptake and distribution of APIs and are likely to prove 
valuable to commercial pharmaceutical research. 
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Figure 4. Illustraation of case studies. A. Comparison of fluorescence and Raman imaging techniques to study the localisation 
of nanoparticles (40 nm diameter) in porated skin. Green: fluorescence, Red: CARS; Blue: SRS. Reprinted from reference 
41
, 
with permission from Elsevier. B. Overlay of ToF-SIMS images of HeLa cells containing 24 slices obtained by depth profiling 
with a C60
+
 cluster ion beam. Red: CxHyOz
-
; Blue: bromodeoxyuridine. Image size: 202 x 202 m
2
. Reprinted with permission 
from reference 
64
. Copyright 2013 American Chemical Society. C. 3D ToF-SIMS image of a 14 m thick rat brain slice obtained 
by depth profiling with an Ar1500
+
 cluster source. Analysed area: 150 x 150 m. Reprinted with permission from reference 
69
. 
Copyright 2013 American Chemical Society. 
 
 
 
 
5. CONCLUSIONS 
 
Surface and interface analysis has been an important aspect of pharmaceutical research for many years and provided 
significant insight into pharmaceutical problems. Several recent examples have been highlighted here to illustrate how state of 
the art analysis techniques can elucidate important aspects of pharmaceutical applications such as the surface properties of 
pharmaceutical formulations and their interfacial interactions during administration. The ongoing development of instrumental 
capabilities will continue to contribute to the advancement of our understanding of interfacial phenomena in drug formulation, 
administration and manufacturing.  
 
The recent progress and prospects for a number of powerful surface analysis techniques discussed here illustrate that 
technological advancement is critically reliant on close collaborations between industry and academia. Translation of these 
novel or advanced technologies to industry is not straightforward but can be facilitated by collaborative centres that provide the 
necessary access to facilities and expertise. The combined development of technological and infrastructural capabilities in 
surface and interface analysis presents the pharmaceutical sector with the necessary prerequisites to tackle important 
challenges in drug discovery and development. Surface and interface analysis can be expected to continue to play a significant 
role in addressing the scientific pharmaceutical challenges that lie ahead and improve the R&D pipeline of pharmaceutical 
products. 
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